Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports

Eligibility Criteria:

1. Age 18-75 years;

2. Patients with malignant tumors who received implantable access ports for treatment;

3. Eastern Cooperative Oncology Group (ECOG) class 0-1;

4. will have a life expectancy > 3 months;

5. Expected survival of more than 6 months;

6. Khorana score ≥2 point.

Exclusion Criteria:

1. Patients with a history of allergies to rivaroxaban;

2. History of recent major or clinically relevant bleeding within the previous 4 weeks.

3. Patients with bleeding risks: thrombocytopenia (platelet count < 50*109/L), clinicallysignificant active bleeding, active gastric ulcer disease, severe arterialhypertension, history of previous stroke; Inadequate renal function; creatinineclearance < 30 ml/min；

4. Inadequate hepatic function: aminotransferase > 3 times the upper limit of normal (ULN) (if liver metastasis, alanine aminotransferase > 5 times the ULN

5. Patients requiring strong cytochrome P450 3A4 (CYP3A4) inducers (rifampin,phenobarbital) or strong CYP3A4 inhibitors (HIV protease inhibitor, systemicketoconazole) treatments.

6. Plan of treatment with bevacizumab or other anti-cancer drugs known to increase thebleeding risk.

7. Patients who have had anticoagulant drugs for any other reason.

8. Women who are pregnant or breastfeeding.